• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Characterization of private mutations in the spike protein of SARS-CoV-2 correlates with viral prevalence

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2025 Aug 8;25(1):996.
doi: 10.1186/s12879-025-11414-3. Characterization of private mutations in the spike protein of SARS-CoV-2 correlates with viral prevalence

Shuo Wang[SUP] #[/SUP][SUP] 1 [/SUP], Ziyang Hao[SUP] #[/SUP][SUP] 1 [/SUP], Yuhan Ding[SUP] 2 [/SUP], Heng Rong[SUP] 2 [/SUP], Shuo Ning[SUP] 2 [/SUP], Qiao Qiao[SUP] 2 [/SUP], Xiaojuan Zhu[SUP] 2 [/SUP], Tao Wu[SUP] 2 [/SUP], Kangchen Zhao[SUP] 2 [/SUP], Liguo Zhu[SUP] 2 [/SUP], Jingxin Li[SUP] 2 [/SUP], Yiyue Ge[SUP] 3 4 [/SUP], Lunbiao Cui[SUP] 5 6 7 [/SUP]



Affiliations
Abstract

Background: SARS-CoV-2 has continued to spread globally since its outbreak. As the virus evolves, new variants affect the efficacy of current vaccines and treatments. Therefore, understanding and explaining the viral prevalence of SARS-CoV-2 is crucial for developing effective public health strategies.
Methods: Genomic information from the SARS-CoV-2 network surveillance laboratories in Jiangsu Province in 2023 was collected. The impact of private mutations on binding affinity of the spike protein to Angiotensin Converting Enzyme 2 (ACE2) was evaluated by Bioinformatic analyses, pseudovirus infection assays and Bio-Layer Interferometry (BLI). The impact of private mutations on antibody escape capacity was evaluated through Pseudotyped Virus Neutralization Assay (PVNA).
Results: The major circulating SARS-CoV-2 sublineages in Jiangsu Province in 2023 included BA.5.2*, XBB.1.5*, XBB.1.16*, XBB.1.22*, and XBB.1.9*. Key private mutations analyzed were E748V in XBB.1.5.24, H146K and I210T in XBB.1.22.1, H146K + I210T, and L455F in EG.5.1/EG.5.1.1. Bioinformatic analyses, pseudovirus infection assays, and BLI results showed that L455F significantly increased the spike protein's binding affinity to ACE2. PVNA results indicated that H146K and I210T enhance the antibody evasion ability of the XBB.1.22.1 spike protein, while L455F did so for EG.5.1/EG.5.1.1. However, E748V increased antibody neutralization sensitivity for XBB.1.5.24. E748V, I210T, and L455F became characteristic of their respective descent lineages GF.1, FY.3.1, and HK.3. The epidemic durations of FY.3.1 and HK.3 were longer than that of GF.1.
Conclusions: Continuous monitoring and functional analysis of SARS-CoV-2 private mutations can be an effective approach for explaining patterns of viral prevalence. This has significant implications for the timely formulation of prevention and control measures.

Keywords: Epidemic; Private mutations; SARS-CoV-2; Spike protein.

 
Back
Top